Cargando…

A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report

BACKGROUND: Spinal cord astrocytoma is a rare neoplasm, and patients usually recur within months after surgery. There is currently a lack of consensus regarding post-operative treatment. Clinical data on the activity of systemic treatment like chemoradiotherapy and anti-angiogenic agents also remain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jietao, Yu, Ling, Fu, Yuanfeng, Chen, Hanrui, Zheng, Xinting, Wang, Shutang, Gao, Chan, Cao, Yang, Lin, Lizhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346338/ https://www.ncbi.nlm.nih.gov/pubmed/32641004 http://dx.doi.org/10.1186/s12885-020-07061-3

Ejemplares similares

Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB–IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial
por: Lin, Jietao, et al.
Publicado: (2022)

CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair
por: Xie, Xianhe, et al.
Publicado: (2019)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
por: Qi, Xiangjun, et al.
Publicado: (2022)

Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement
por: Yu, Ling, et al.
Publicado: (2023)

Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)
por: Lin, Jietao, et al.
Publicado: (2023)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review
por: Lin, Jietao, et al.
Publicado: (2018)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Translating palbociclib to the clinic for DIPG - What is truly achievable?
por: Franshaw, Laura, et al.
Publicado: (2019)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Lung abscess secondary to lung cancer with Eikenella corrodens and Streptococcus anginosus: a case report
por: Hu, Leihao, et al.
Publicado: (2020)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Effect of Fatigue Three-Needle acupuncture therapy in a patient with cancer-related fatigue: A case report
por: He, Lijun, et al.
Publicado: (2019)

Authors' Reply to “Translating palbociclib to the clinic for DIPG - What is truly achievable?”
por: Sun, Yu, et al.
Publicado: (2019)

Effect of Chinese Herbal Medicine on the Survival of Colorectal Cancer Patients With Liver-Limited Metastases: A Retrospective Cohort Study, 2008 to 2017
por: Shao, Cui, et al.
Publicado: (2019)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

Palbociclib: COVID-19 infection: case report
Publicado: (2020)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study
por: Chen, Wenmin, et al.
Publicado: (2023)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
por: Hsieh, Feng‐Shu, et al.
Publicado: (2017)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Sunitinib-and-Chinese herbal medicine-based systematic treatment clinically cured a patient with multiple metastatic primary clear cell carcinoma of the liver: a case report
por: Sun, Lingling, et al.
Publicado: (2019)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Network Pharmacology/Metabolomics-Based Validation of AMPK and PI3K/AKT Signaling Pathway as a Central Role of Shengqi Fuzheng Injection Regulation of Mitochondrial Dysfunction in Cancer-Related Fatigue
por: Guo, Wei, et al.
Publicado: (2021)

Estradiol regulates oxidative stress and angiogenesis of myocardial microvascular endothelial cells via the CDK1/CDK2 pathway
por: Zhou, Ke, et al.
Publicado: (2023)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
por: Yang, Lishu, et al.
Publicado: (2018)

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
por: Miettinen, Teemu P, et al.
Publicado: (2018)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
por: Pennycook, Betheney R., et al.
Publicado: (2021)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

Exemestane/palbociclib/prednisolone: Various toxicities: case report
Publicado: (2020)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4cllhq5ln99o6okb0pbq9ignnt